查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529615

核子医学市场规模、份额和趋势分析：2024-2030 年按产品、应用、最终用途、地区和细分市场进行的预测

Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10个工作天内

价格

核子医学市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球核医市场规模将达到345.1亿美元，2024年至2030年复合年增长率为11.69%。

癌症和甲状腺等慢性病盛行率的增加预计将推动市场成长。在预测期内多种放射性药物疗法即将获得核准将是市场的主要驱动因素。例如，2022年3月，诺华公司的Pluvicto（Lu 177）获得核准用于治疗成年前列腺癌患者。

根据泛美卫生组织（PAHO）估计，2022年全球将有约2,000万人新诊断出癌症，约1,000万人将死于此病。低收入和中等收入国家生活方式的改变、不健康的饮食和口腔健康意识低等因素是癌症盛行率最常见的原因。

诊断中越来越多地采用核医学产品以及核准新发生器以帮助增加放射性核素的供应预计将推动成长。例如，2021年11月，EZAG在巴西获得了GalliaPharm旗下巴西卫生局监管机构（ANVISA）的核准。这是一种镓 68 产生器，用于从崩坏的锗 68 源中提取正子发射镓同位素，以生产 G68 Dotatate 注射液。这是巴西第一个也是唯一一个核准作为药物的镓发生器。此类产品的核准将有助于发展中市场的市场成长。

鑑于COVID-19大流行，市场受到中等程度的影响。 2020 年第二季度，核能(IAEA) 对基于核子反应炉的医用同位素进行了研究，以评估 COVID-19 危机期间供应链的连续性。结果显示，主要生产商继续以国际原子能总署的安全标准进行生产。

核子医学市场报告亮点

  • 按产品类型划分，SPECT 细分市场由于成本低、精度高且在各种应用中广泛使用，在诊断市场中占据最大份额。
  • 由于用于前列腺癌的 PYLARIFY PET 显影剂等新产品的核准和推出，预计 PET 领域将在预测期内显着增长。
  • 从应用来看，肿瘤学领域将在 2023 年占据市场主导地位。
  • 2023年，北美地区将以42.96%的份额占据市场主导地位。这是由于对目前治疗方法的认识提高、有利的报销政策以及患者经济负担的减轻。
  • 由于预测期内慢性病盛行率上升、老年人口增加以及新产品的核准，预计亚太地区将成为未来成长最快的地区。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章核子医学市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 核子医学市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章 核子医学市场：产品预估及趋势分析

  • 全球核子医学市场：产品仪表板
  • 全球核子医学市场：产品变异分析
  • 全球核子医学市场：按产品、收益
  • 诊断
  • 治疗

第五章 核子医学市场：应用预估及趋势分析

  • 全球核子医学市场：应用仪表板
  • 全球核子医学市场：应用变迁分析
  • 按使用情况分類的收益
  • 心臟病
  • 神经病学
  • 瘤
  • 甲状腺
  • 淋巴瘤
  • 骨转移
  • 内分泌肿瘤
  • 肺部扫描
  • 泌尿系统
  • 其他的

第六章 核子医学市场：最终用途估计与趋势分析

  • 全球核子医学市场：最终用途仪表板
  • 全球核子医学市场：最终用途变化分析
  • 按最终用途分類的收益
  • 医院
  • 诊断中心
  • 其他的

第七章 核医市场：按产品、按应用、按最终用途分类的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030 年市场规模、预测/趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • GE Healthcare.
    • Jubilant Life Sciences Ltd
    • Nordion（Canada）, Inc.
    • Bracco Imaging SPA
    • The Institute for Radioelements（IRE）
    • NTP Radioisotopes SOC Ltd.
    • The Australian Nuclear Science and Technology Organization
    • EczacIbasI-Monrol
    • Lantheus Medical Imaging, Inc.
    • Eckert &Ziegler.
    • Mallinckrodt.
    • Cardinal Health.
Product Code: GVR-1-68038-086-6

Nuclear Medicine Market Growth & Trends:

The global nuclear medicine market size is expected to reach USD 34.51 billion by 2030, registering a CAGR of 11.69% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.

According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.

Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency's (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.

In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.

Nuclear Medicine Market Report Highlights:

  • By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
  • The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
  • By application, the oncology segment dominated the market in 2023.
  • North America dominated the market with a share of 42.96% in 2023, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
  • The Asia Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Nuclear Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
      • 3.2.1.2. Increasing application of radiopharmaceuticals/nuclear medicine
      • 3.2.1.3. Growing demand for accurate diagnostic methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Stringent regulations pertaining to production, storage, & usage
  • 3.3. Nuclear Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Nuclear Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Global Nuclear Medicine Market: Product Dashboard
  • 4.2. Global Nuclear Medicine Market: Product Movement Analysis
  • 4.3. Global Nuclear Medicine Market By Product, Revenue
  • 4.4. Diagnostics
    • 4.4.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. SPECT
      • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. TC-99m
      • 4.4.2.2.1. TC-99m market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. TL-201
      • 4.4.2.3.1. TL-201 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. GA-67
      • 4.4.2.4.1. GA-67 markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. I-123
      • 4.4.2.5.1. I-123 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.6. Others
      • 4.4.2.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. PET
      • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.2. F18
      • 4.4.3.2.1. F18 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.3. SR-82/RB-82
      • 4.4.3.3.1. SR-82/RB-82 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.4. PYLARIFY (piflufolastat F 18)
      • 4.4.3.4.1. PYLARIFY (piflufolastat F 18) markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.5. Illuccix (gallium Ga 68 gozetotide)
      • 4.4.3.5.1. Illuccix (gallium Ga 68 gozetotide)s market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.6. Others
      • 4.4.3.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Therapeutics
    • 4.5.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Alpha Emitters
      • 4.5.2.1. Alpha emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.2. RA-223
      • 4.5.2.2.1. RA-223 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.3. Others
      • 4.5.2.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Beta Emitters
      • 4.5.3.1. Beta emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.2. I-131
      • 4.5.3.2.1. I-131 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.3. Y-90
      • 4.5.3.3.1. Y-90 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.4. SM-153
      • 4.5.3.4.1. SM-153 markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.5. Re-186
      • 4.5.3.5.1. Re-186 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.6. Lu-177
      • 4.5.3.6.1. Lu-177 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.7. Others
      • 4.5.3.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Brachytherapy
      • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.2. Cesium-131
      • 4.5.4.2.1. Cesium-131 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.3. Iodine-125
      • 4.5.4.3.1. Iodine-125 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.4. Palladium-103
      • 4.5.4.4.1. Palladium-103 markets estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.5. Iridium-192
      • 4.5.4.5.1. Iridium-192 market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.6. Others
      • 4.5.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Nuclear Medicine Market: Application Estimates & Trend Analysis

  • 5.1. Global Nuclear Medicine Market: Application Dashboard
  • 5.2. Global Nuclear Medicine Market: Application Movement Analysis
  • 5.3. Global Nuclear Medicine Market Estimates and Forecasts, By Application, Revenue (USD Million)
  • 5.4. Cardiology
    • 5.4.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. SPECT
      • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. PET
      • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Therapeutic Applications
      • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Neurology
    • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Thyroid
    • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. SPECT
      • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. Therapeutic Applications
      • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Lymphoma
    • 5.8.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Bone Metastasis
    • 5.9.1. Bone metastasis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.2. SPECT
      • 5.9.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.3. Therapeutic Applications
      • 5.9.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Endocrine Tumor
    • 5.10.1. Endocrine tumor market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.11. Pulmonary Scans
    • 5.11.1. Pulmonary scans market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.12. Urology
    • 5.12.1. Urology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.13. Others
    • 5.13.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Nuclear Medicine Market: End Use Estimates & Trend Analysis

  • 6.1. Global Nuclear Medicine Market: End Use Dashboard
  • 6.2. Global Nuclear Medicine Market: End Use Movement Analysis
  • 6.3. Global Nuclear Medicine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Centers
    • 6.5.1. Diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Nuclear Medicine Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. GE Healthcare.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Jubilant Life Sciences Ltd
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Nordion (Canada), Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Bracco Imaging S.P.A
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. The Institute for Radioelements (IRE)
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. NTP Radioisotopes SOC Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. The Australian Nuclear Science and Technology Organization
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. EczacIbasI-Monrol
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Lantheus Medical Imaging, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Eckert & Ziegler.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Mallinckrodt.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
    • 8.3.15. Cardinal Health.
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 17 Germany nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 20 UK nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 23 France nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 24 France nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 26 Italy nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 29 Spain nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 32 Denmark nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 35 Sweden nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 38 Norway nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 43 Aisa Pacific nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 45 China nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 46 China nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 48 Japan nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 51 India nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 52 India nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 54 South Korea nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 57 Australia nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 60 Thailand nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 64 Latin America nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 67 Brazil nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 70 Mexico nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 73 Argentina nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA nuclear medicine market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 77 MEA nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 78 MEA nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 80 South Africa nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 86 UAE nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE nuclear medicine market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait nuclear medicine market, by product, 2018 - 2030 (USD Million)
  • Table 89 Kuwait nuclear medicine market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait nuclear medicine market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Nuclear medicine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Nuclear medicine market snapshot
  • Fig. 10 Nuclear medicine market driver impact
  • Fig. 11 Global cancer cases projections - 2030 (Number of new registered cases)
  • Fig. 12 Nuclear medicine market restraint impact
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Value chain analysis
  • Fig. 16 Nuclear medicine market: Production of Tc-99 (SPECT radioisotopes)
  • Fig. 17 Nuclear medicine market: Production of 18F-FDG (PET radioisotopes)
  • Fig. 18 Company market share analysis
  • Fig. 19 Company market position analysis
  • Fig. 20 Company market position analysis
  • Fig. 21 Competitive dashboard analysis
  • Fig. 22 Regional network map
  • Fig. 23 Nuclear medicine market: Product outlook and key takeaways
  • Fig. 24 Nuclear medicine market: Product movement analysis
  • Fig. 25 Diagnostic products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 PET products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 PYLARIFY (piflufolastat F 18) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Illuccix (gallium Ga 68 gozetotide) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Therapeutic products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Nuclear medicine market: Application outlook and key takeaways
  • Fig. 56 Nuclear medicine market: Application movement analysis
  • Fig. 57 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Thyroid market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Bone metastasis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Endocrine tumor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Pulmonary scans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Urology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Nuclear medicine market: End-use outlook and key takeaways
  • Fig. 68 Nuclear medicine market: End-use movement analysis
  • Fig. 69 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Global nuclear medicine market: Regional movement analysis
  • Fig. 73 Global nuclear medicine market: Regional outlook and key takeaways
  • Fig. 74 Global nuclear medicine market share and leading players
  • Fig. 75 North America, by country
  • Fig. 76 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. key country dynamics
  • Fig. 78 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Canada key country dynamics
  • Fig. 80 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Mexico key country dynamics
  • Fig. 82 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 UK key country dynamics
  • Fig. 85 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Germany key country dynamics
  • Fig. 87 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 France key country dynamics
  • Fig. 89 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Italy key country dynamics
  • Fig. 91 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Spain key country dynamics
  • Fig. 93 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Denmark key country dynamics
  • Fig. 95 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Sweden key country dynamics
  • Fig. 97 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Norway key country dynamics
  • Fig. 99 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 China key country dynamics
  • Fig. 102 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Japan key country dynamics
  • Fig. 104 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 India key country dynamics
  • Fig. 106 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Thailand key country dynamics
  • Fig. 108 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 South Korea key country dynamics
  • Fig. 110 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Australia key country dynamics
  • Fig. 112 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Brazil key country dynamics
  • Fig. 115 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Argentina key country dynamics
  • Fig. 117 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 South Africa key country dynamics
  • Fig. 120 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Saudi Arabia key country dynamics
  • Fig. 122 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 UAE key country dynamics
  • Fig. 124 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Kuwait key country dynamics
  • Fig. 126 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Market share of key market players- nuclear medicine market